/PRNewswire/ TrialSpark, a tech-driven drug developer with its own portfolio of clinical stage drug assets, is rebranding to Formation Bio. The new name is.
/PRNewswire/ TrialSpark, Inc. announced today that the first patient has been dosed in its Phase 2 clinical trial for ASN008-201, a topical sodium channel.
/PRNewswire/ TrialSpark announced today the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology.